Comprehensive Clinical Guide: Dieulafoy’s Lesion

1. Introduction and Overview

Dieulafoy’s lesion (DL) remains one of the most clinically challenging and potentially life-threatening causes of gastrointestinal (GI) hemorrhage. Despite being a relatively rare entity—accounting for approximately 1% to 2% of all acute GI bleeds—it is frequently underdiagnosed due to its subtle endoscopic appearance and the intermittent nature of its bleeding.

Formally defined as a large-caliber, submucosal artery that erodes through the overlying mucosa without the presence of an underlying ulcer, Dieulafoy’s lesion presents a "clinical paradox." While the lesion itself is minute, the resultant hemorrhage is often massive, arterial, and sudden. First described by the French surgeon Georges Dieulafoy in 1898 as exulceratio simplex, the condition requires a high index of clinical suspicion, particularly in patients presenting with unexplained, recurrent hematemesis or melena.

2. Pathophysiology and Technical Mechanisms

The Vascular Anomaly

The fundamental pathophysiology of Dieulafoy’s lesion involves a persistent caliber artery. Unlike normal mucosal arterioles that taper as they reach the mucosal layer, the vessel involved in a Dieulafoy’s lesion maintains a constant diameter (often 1–3 mm).

The Mechanism of Erosion

The erosion is not caused by inflammation (as in peptic ulcer disease) but rather by mechanical pressure. The persistent, pulsatile artery exerts pressure on the overlying mucosa, leading to pressure necrosis, thinning, and eventual rupture.

Anatomical Distribution

While most commonly found in the stomach—specifically along the lesser curvature within 6 cm of the gastroesophageal junction—Dieulafoy’s lesions can occur anywhere within the gastrointestinal tract.

• Gastric (Proximal): ~75-80%
• Small Intestine (Duodenum/Jejunum): ~15%
• Colon/Rectum: ~5%
• Esophagus: <5%

3. Clinical Indications and Diagnostic Approach

Standard Presentation

The classic presentation is a patient—often elderly with multiple comorbidities—who experiences sudden, painless, massive hematemesis or melena. Unlike peptic ulcer disease, the patient typically lacks a history of NSAID use or dyspepsia.

Diagnostic Modalities

Diagnosis is primarily endoscopic. However, the transient nature of the lesion makes it notoriously difficult to identify.

1. Esophagogastroduodenoscopy (EGD): The gold standard. A successful diagnosis requires careful inspection of the mucosa. The lesion may appear as a small, isolated protuberance with a "spurting" vessel or a clot adherent to a tiny mucosal defect.
2. Endoscopic Ultrasound (EUS): Increasingly used to identify the underlying large-caliber vessel if standard EGD is inconclusive.
3. CT Angiography (CTA): Highly sensitive for active bleeding sites. Useful in patients who are hemodynamically unstable and cannot undergo endoscopy.
4. Angiography (Selective): Used when endoscopy fails to locate the bleed or if the hemorrhage is too profuse for visualization.

Differential Diagnosis

The clinical team must differentiate Dieulafoy’s from other sources of upper GI bleeding:
* Peptic Ulcer Disease (PUD)
* Mallory-Weiss tears
* Esophageal varices
* Angiodysplasia
* Gastric Antral Vascular Ectasia (GAVE)

4. Clinical Staging and Grading

There is no universally accepted "Staging System" for Dieulafoy’s, but clinicians utilize the Forrest Classification (originally for ulcers) to categorize the bleeding risk:

5. Risks, Contraindications, and Management

Therapeutic Management

The treatment of choice is endoscopic intervention. If the lesion is identified, therapeutic success is generally high.

• Mechanical Therapy: Endoscopic hemoclips are the preferred method. They provide immediate hemostasis and are less damaging to the surrounding tissue than thermal methods.
• Thermal Therapy: Bipolar electrocoagulation or heater probes can be used, though they carry a higher risk of perforation.
• Injection Therapy: Epinephrine injection is often used as an adjunct to mechanical or thermal therapy to reduce blood flow and improve visibility.

Risks and Complications

• Perforation: A major risk during thermal therapy, especially in the thin-walled areas of the stomach.
• Re-bleeding: Occurs in approximately 10-15% of cases, usually within the first 48 hours.
• Missed Diagnosis: The greatest risk is failing to identify the lesion during the initial EGD, leading to repeated, life-threatening episodes.

Contraindications for Endoscopic Therapy

• Severe hemodynamic instability (requires surgical intervention/laparotomy).
• Inability to visualize the lesion despite multiple attempts.
• Failed endoscopic therapy (two or more failed attempts).

6. Long-Term Prognosis

The prognosis for Dieulafoy’s lesion is excellent once the diagnosis is confirmed and treated. The mortality rate, which was historically high (up to 80% in the pre-endoscopic era), has plummeted to <5% with modern endoscopic techniques. Patients generally do not require long-term PPI therapy or surgical resection unless the lesion is recurrent and refractory to all endovascular measures.

7. Massive FAQ Section

1. Is Dieulafoy’s lesion a type of cancer?
No. It is a vascular anomaly, not a malignancy. It is a structural abnormality of an artery.

2. Why is it so hard to find during an endoscopy?
The lesion is often small, and if it is not actively bleeding, it can look like a normal mucosal fold. Once the bleeding stops, the vessel may retract, making it invisible to the endoscopist.

3. Does Dieulafoy’s lesion cause pain?
Usually, no. Unlike peptic ulcers, which are inflammatory, Dieulafoy’s is a pressure-based vascular event, making it typically painless.

4. Are there specific risk factors?
Yes. It is more common in males and the elderly. Comorbidities such as hypertension, chronic kidney disease, and cardiovascular disease are frequently associated.

5. What is the first-line treatment?
Endoscopic mechanical clipping is currently considered the gold standard for its efficacy and safety profile.

6. Can it recur after treatment?
Recurrence is possible but rare (roughly 10%). If it recurs, it is usually managed with repeat endoscopy or, in rare cases, angiographic embolization.

7. Is surgery ever required?
Surgery is reserved for cases where endoscopic therapy fails or the patient is too unstable to tolerate the procedure.

8. What role do NSAIDs play?
Unlike peptic ulcers, Dieulafoy’s lesions are not caused by NSAIDs. However, NSAIDs may exacerbate bleeding from an already compromised vessel.

9. Can Dieulafoy’s occur in the colon?
Yes. While the stomach is the most common site, colonic Dieulafoy’s is a well-documented entity and represents a common cause of lower GI hemorrhage in older adults.

10. Do I need a follow-up endoscopy?
Routine follow-up is not typically required unless there are signs of recurrent bleeding (melena or hematemesis).

8. Summary for Clinicians

Dieulafoy’s lesion is a "hidden" pathology that demands vigilance. When a patient presents with significant GI bleeding and no obvious source on initial inspection, the endoscopist must perform a meticulous examination of the gastric cardia and lesser curvature. By maintaining a high index of suspicion and utilizing modern endoscopic clipping techniques, clinicians can successfully treat this life-threatening condition with minimal morbidity.

Disclaimer: This guide is intended for educational purposes for healthcare professionals and students. It does not constitute medical advice. Clinical decisions should be based on institutional protocols and individual patient assessment.